Pleural mesothelioma (Homo sapiens)

From WikiPathways

Revision as of 08:20, 17 June 2021 by Finterly (Talk | contribs)
Jump to: navigation, search
14-3-314-3-32422425552552234344363225223562232, 325633243332256462546MMChronic inflammation, proliferation, angiogenesis,resistance to apoptosisGFsTAMsCo-factorUbiquination degradationCell survivalAAutophagyRTKsDNA-damageCell cycle progression &ProliferationIntegrinsOther chemokines/cytokinesChemokines, Cytokines,Pro-angiogenic factorsB, CCell growth,differentiationCell invasionIncreased protein synthesis+ Cell growthDNA-repairGrowth arrestCadherinsCell growthDegradationApoptosisWnt signalIAP-1 dependent genes/Repair genesEHDInflammatory cytokines,cellular stressesChemokines/Cytokines etc.NeoangiogenesisFTranscriptionBTCFPTENc-junFOXO1AJUBAc-fosPIP2S6KMTORLATS1/2DVLEIF4MEKKSRCRICTORDKK1GRB2P14ARFMMP9MDM2CyclinESTATHMGB1BTRCfra-1KIBRA14-3-3FAKBAP1PI3KLEFPIGFATMMEK1/2TSC2JNK1-3TSC1ERK1/2TTI1PAK/RACMLKHIF1ARHEBPRAS40TEADRAGEAMOT4E-BPSOSMEK5PIP3IL-1BMEK3/6RAFFIP200DEPTORMAPK14PRBFZDGDPCDK4ULK1MSIN1CDK2RASPDK1DR5S6LRPMEK4/7SAV1CASPASE-1ATG13BCL2RAPTORE2FMCL1GSK3ERK5ROSMKTEL2BCLXLBAXMLST8P53AXINPDGFJAKRSKP16INK4ACUL1BAKMST1/2SFRPNF2/merlinNLRP3ASKCTNNBL1Cyclin DSHCGTPMNKNF-KBCyclinD1P21PUMAVEGFERK2CDK7BECLIN1MMP2MSKAPCRNSAKTRASMSKMNKMKTEL2TTI1MLST8DEPTORMTORYAPTAZMDM2CTNNBL1P21BAXTAZCTNNBL1CTNNBL1Cell transformationTFCo-TFE2FPRBHMGB1HMGB1PRAS40RAPTORTEL2TTI1MLST8DEPTORMTORHMGB1IL-1BPro IL-1BP21YAPTAZChemokines, Cytokines,Pro-angiogenic factorsCell survival2


Description

Malignant Pleural Mesothelioma is a rare cancer affecting the mesothelial cells of the lungs. 80% of the patients have been exposed to asbestos before being diagnosed, but only 5% of the people exposed to asbestos develop mesothelioma. Therefore, genetics are thought to play an important role in combination with asbestos' toxicological effects. Several pathways have been identified to contribute to the development of the disease.

Try the New WikiPathways

View approved pathways at the new wikipathways.org.

Quality Tags

Ontology Terms

 

Bibliography

View all...
  1. Chu GJ, van Zandwijk N, Rasko JEJ; ''The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy.''; Front Oncol, 2019 PubMed Europe PMC Scholia
  2. Mossman BT, Shukla A, Heintz NH, Verschraegen CF, Thomas A, Hassan R; ''New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.''; Am J Pathol, 2013 PubMed Europe PMC Scholia
  3. Bitra A, Sistla S, Mariam J, Malvi H, Anand R; ''Rassf Proteins as Modulators of Mst1 Kinase Activity.''; Sci Rep, 2017 PubMed Europe PMC Scholia
  4. Hylebos M, Van Camp G, Vandeweyer G, Fransen E, Beyens M, Cornelissen R, Suls A, Pauwels P, van Meerbeeck JP, Op de Beeck K; ''Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma.''; Oncotarget, 2017 PubMed Europe PMC Scholia
  5. Liu XL, Zuo R, Ou WB; ''The hippo pathway provides novel insights into lung cancer and mesothelioma treatment.''; J Cancer Res Clin Oncol, 2018 PubMed Europe PMC Scholia
  6. Yuan X, Dai M, Xu D; ''TERT promoter mutations and GABP transcription factors in carcinogenesis: More foes than friends.''; Cancer Lett, 2020 PubMed Europe PMC Scholia
  7. Dratwa M, Wysoczańska B, Łacina P, Kubik T, Bogunia-Kubik K; ''TERT-Regulation and Roles in Cancer Formation.''; Front Immunol, 2020 PubMed Europe PMC Scholia
  8. Masclef L, Ahmed O, Estavoyer B, Larrivée B, Labrecque N, Nijnik A, Affar EB; ''Roles and mechanisms of BAP1 deubiquitinase in tumor suppression.''; Cell Death Differ, 2021 PubMed Europe PMC Scholia
  9. Sekido Y; ''Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.''; Cancers (Basel), 2018 PubMed Europe PMC Scholia
  10. Coleman SJ, Bruce C, Chioni AM, Kocher HM, Grose RP; ''The ins and outs of fibroblast growth factor receptor signalling.''; Clin Sci (Lond), 2014 PubMed Europe PMC Scholia
  11. Volodko N, Gordon M, Salla M, Ghazaleh HA, Baksh S; ''RASSF tumor suppressor gene family: biological functions and regulation.''; FEBS Lett, 2014 PubMed Europe PMC Scholia
  12. Napoli F, Listì A, Zambelli V, Witel G, Bironzo P, Papotti M, Volante M, Scagliotti G, Righi L; ''Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma.''; Cancers (Basel), 2021 PubMed Europe PMC Scholia
  13. Liu Z, Klominek J; ''Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors.''; Thorax, 2003 PubMed Europe PMC Scholia
  14. Marie-Claude Jaurand, Didier Jean; ''Biomolecular Pathways and Malignant Pleural Mesothelioma''; Malignant Pleural Mesothelioma: Present Status and Future Directions, 2015 DOI Scholia
  15. Zanconato F, Cordenonsi M, Piccolo S; ''YAP/TAZ at the Roots of Cancer.''; Cancer Cell, 2016 PubMed Europe PMC Scholia
  16. Kato S, Tomson BN, Buys TP, Elkin SK, Carter JL, Kurzrock R; ''Genomic Landscape of Malignant Mesotheliomas.''; Mol Cancer Ther, 2016 PubMed Europe PMC Scholia
  17. Dobrokhotov O, Samsonov M, Sokabe M, Hirata H; ''Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms.''; Clin Transl Med, 2018 PubMed Europe PMC Scholia
  18. Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G; ''BAP1 and cancer.''; Nat Rev Cancer, 2013 PubMed Europe PMC Scholia
  19. Klominek J, Sumitran Karuppan S, Hauzenberger D; ''Differential motile response of human malignant mesothelioma cells to fibronectin, laminin and collagen type IV: the role of beta1 integrins.''; Int J Cancer, 1997 PubMed Europe PMC Scholia
  20. Pirker C, Bilecz A, Grusch M, Mohr T, Heidenreich B, Laszlo V, Stockhammer P, Lötsch-Gojo D, Gojo J, Gabler L, Spiegl-Kreinecker S, Dome B, Steindl A, Klikovits T, Hoda MA, Jakopovic M, Samarzija M, Mohorcic K, Kern I, Kiesel B, Brcic L, Oberndorfer F, Müllauer L, Klepetko W, Schmidt WM, Kumar R, Hegedus B, Berger W; ''Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup.''; Clin Cancer Res, 2020 PubMed Europe PMC Scholia
  21. Illei PB, Ladanyi M, Rusch VW, Zakowski MF; ''The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.''; Cancer, 2003 PubMed Europe PMC Scholia
  22. Yuan X, Larsson C, Xu D; ''Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players.''; Oncogene, 2019 PubMed Europe PMC Scholia
  23. Hylebos M, Van Camp G, van Meerbeeck JP, Op de Beeck K; ''The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing.''; J Thorac Oncol, 2016 PubMed Europe PMC Scholia
  24. Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M, Pellegrini L, Signorato V, Olivetto F, Pastorino S, Nasu M, Napolitano A, Gaudino G, Morris P, Sakamoto G, Ferris LK, Danese A, Raimondi A, Tacchetti C, Kuchay S, Pass HI, Affar EB, Yang H, Pinton P, Carbone M; ''BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation.''; Nature, 2017 PubMed Europe PMC Scholia
  25. Benedetti S, Nuvoli B, Catalani S, Galati R; ''Reactive oxygen species a double-edged sword for mesothelioma.''; Oncotarget, 2015 PubMed Europe PMC Scholia
  26. Morani F, Bisceglia L, Rosini G, Mutti L, Melaiu O, Landi S, Gemignani F; ''Identification of Overexpressed Genes in Malignant Pleural Mesothelioma.''; Int J Mol Sci, 2021 PubMed Europe PMC Scholia
  27. Obacz J, Yung H, Shamseddin M, Linnane E, Liu X, Azad AA, Rassl DM, Fairen-Jimenez D, Rintoul RC, Nikolić MZ, Marciniak SJ; ''Biological basis for novel mesothelioma therapies.''; Br J Cancer, 2021 PubMed Europe PMC Scholia
  28. Yap TA, Aerts JG, Popat S, Fennell DA; ''Novel insights into mesothelioma biology and implications for therapy.''; Nat Rev Cancer, 2017 PubMed Europe PMC Scholia
  29. Cakiroglu E, Senturk S; ''Genomics and Functional Genomics of Malignant Pleural Mesothelioma.''; Int J Mol Sci, 2020 PubMed Europe PMC Scholia
  30. Tallet A, Nault JC, Renier A, Hysi I, Galateau-Sallé F, Cazes A, Copin MC, Hofman P, Andujar P, Le Pimpec-Barthes F, Zucman-Rossi J, Jaurand MC, Jean D; ''Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma.''; Oncogene, 2014 PubMed Europe PMC Scholia
  31. Eletr ZM, Wilkinson KD; ''An emerging model for BAP1's role in regulating cell cycle progression.''; Cell Biochem Biophys, 2011 PubMed Europe PMC Scholia
  32. Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI; ''Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.''; CA Cancer J Clin, 2019 PubMed Europe PMC Scholia
  33. Chapel DB, Churg A, Santoni-Rugiu E, Tsujimura T, Hiroshima K, Husain AN; ''Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.''; Lung Cancer, 2019 PubMed Europe PMC Scholia
  34. Urso L, Calabrese F, Favaretto A, Conte P, Pasello G; ''Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment.''; Crit Rev Oncol Hematol, 2016 PubMed Europe PMC Scholia
  35. Nusse R; ''Wnt signaling in disease and in development.''; Cell Res, 2005 PubMed Europe PMC Scholia
  36. Crispi S, Calogero RA, Santini M, Mellone P, Vincenzi B, Citro G, Vicidomini G, Fasano S, Meccariello R, Cobellis G, Menegozzo S, Pierantoni R, Facciolo F, Baldi A, Menegozzo M; ''Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target.''; PLoS One, 2009 PubMed Europe PMC Scholia
  37. Edwards JG, McLaren J, Jones JL, Waller DA, O'Byrne KJ; ''Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura.''; Br J Cancer, 2003 PubMed Europe PMC Scholia
  38. Ghareghomi S, Ahmadian S, Zarghami N, Kahroba H; ''Fundamental insights into the interaction between telomerase/TERT and intracellular signaling pathways.''; Biochimie, 2021 PubMed Europe PMC Scholia
  39. Whitson BA, Kratzke RA; ''Molecular pathways in malignant pleural mesothelioma.''; Cancer Lett, 2006 PubMed Europe PMC Scholia

History

View all...
CompareRevisionActionTimeUserComment
127398view20:36, 29 September 2023Khanspersupdated phospho sites
126829view09:08, 26 June 2023Marvin M2Modified description
126828view09:06, 26 June 2023Marvin M2Modified title
125314view21:41, 31 January 2023LarsgwAdd DOI to reference
124802view21:26, 11 December 2022AlexanderPicofixed citations
124785view06:42, 11 December 2022AlexanderPicofixed citations
122659view07:29, 27 April 2022Marvin M2Modified description
120373view20:34, 29 November 2021Marvin M2Connected line
120370view20:20, 29 November 2021Marvin M2Added comments for BAP1
120368view19:57, 29 November 2021Marvin M2Updated BAP1 section
120228view22:12, 15 November 2021Marvin M2Corrected PRC2 interactions
120227view22:05, 15 November 2021Marvin M2minor updates to BAP1 section
120212view21:31, 10 November 2021Marvin M2changed mutated genes view
120211view20:50, 10 November 2021Marvin M2Added HGNC symbols and ensembl IDs
120200view23:19, 8 November 2021ZiskaUpdated Ensembl IDs
120068view18:03, 26 October 2021Marvin M2Reshaped BAP1 section
119947view20:02, 27 September 2021Marvin M2Added list of biomarkers of prognosis
119931view20:20, 22 September 2021Marvin M2Legend added
119827view17:04, 29 August 2021Marvin M2Corrected mutated genes
119809view16:45, 26 August 2021Marvin M2Modified description
119808view15:53, 26 August 2021Marvin M2Added more detail and frequently mutated genes
119807view13:14, 26 August 2021Marvin M2Added MAPK target genes
119806view12:32, 26 August 2021Marvin M2Worked on MAPK pathway
119805view21:15, 25 August 2021Marvin M2Improved top left section
119804view20:04, 25 August 2021Marvin M2Improved, added frequently mutated genes.
119739view08:05, 11 August 2021L DupuisConnected lines
119730view12:29, 10 August 2021ZiskaExtended Wnt pathway
119729view19:44, 9 August 2021ZiskaAdded phosphorylation steps in Hippo signaling
119680view18:06, 28 July 2021EgonwFixed a reference
119679view18:04, 28 July 2021EgonwReplaced secondary ChEBI identifiers with primary ones.
119668view12:40, 28 July 2021Marvin M2Added JNKs
119667view12:22, 28 July 2021Marvin M2Cleaning hippo part
119666view12:11, 28 July 2021Marvin M2Improved hippo pathway part
119659view10:58, 28 July 2021Marvin M2Added content in microenvironment
119654view09:58, 28 July 2021Marvin M2Made space and added microenvironment parts
119642view00:10, 28 July 2021ZiskaExtended Hippo-Merlin signalling
119641view20:58, 27 July 2021Marvin M2Added secretions by mesothelioma
119640view20:12, 27 July 2021Marvin M2Added ECM content, and MMP regulations
119630view20:52, 23 July 2021Marvin M2Added ECM-linked hippo signaling, pathway nodes, and started miroenvironment interactions
119629view13:16, 23 July 2021ZiskaAdded regulation of TERT
119595view11:31, 21 July 2021Marvin M2improved annotations
119594view11:23, 21 July 2021Marvin M2Labels added
119586view08:54, 21 July 2021Marvin M2Red coloring for tumor suppressor genes
119580view15:41, 20 July 2021Marvin M2Minor graphical updates
119579view15:33, 20 July 2021Marvin M2Modified description
119578view15:25, 20 July 2021Marvin M2Added pathway nodes, histone modifications
119576view15:59, 19 July 2021Marvin M2Pathway nodes added
119575view15:46, 19 July 2021Marvin M2Added CDKN2A and transcripts
119568view11:59, 16 July 2021ZiskaChanged shapes and colors and turnt headings into letters
119094view08:20, 17 June 2021FinterlyRemoved PublicationXref and corresponding BiopaxRef with no information

External references

DataNodes

View all...
NameTypeDatabase referenceComment
14-3-3ProteinA0A0J9YWE8 (Uniprot-TrEMBL)
4E-BPGeneProductENSG00000187840 (Ensembl)
AJUBAGeneProductENSG00000129474 (Ensembl)
AKTGeneProductENSG00000142208 (Ensembl)
AMOTGeneProductENSG00000126016 (Ensembl)
APCGeneProductENSG00000134982 (Ensembl)
ASKGeneProductENSG00000115687 (Ensembl)
ATG13GeneProductENSG00000175224 (Ensembl)
ATMGeneProductENSG00000149311 (Ensembl)
AXINGeneProductENSG00000168646 (Ensembl)
BAKGeneProductENSG00000030110 (Ensembl)
BAP1GeneProductENSG00000163930 (Ensembl)
BAXGeneProductENSG00000087088 (Ensembl)
BCL2GeneProductENSG00000171791 (Ensembl)
BCLXLGeneProductENSG00000171791 (Ensembl)
BECLIN1GeneProductENSG00000126581 (Ensembl)
BTRCGeneProductENSG00000166167 (Ensembl)
CASPASE-1GeneProductENSG00000137752 (Ensembl)
CDK2GeneProductENSG00000123374 (Ensembl)
CDK4GeneProductENSG00000135446 (Ensembl)
CDK7GeneProductENSG00000134058 (Ensembl)
CTNNBL1GeneProductENSG00000132792 (Ensembl)
CUL1GeneProductENSG00000055130 (Ensembl)
Cyclin DGeneProductENSG00000110092 (Ensembl)
CyclinD1GeneProductENSG00000110092 (Ensembl)
CyclinEGeneProductENSG00000105173 (Ensembl)
DEPTORGeneProductENSG00000155792 (Ensembl)
DKK1GeneProductENSG00000107984 (Ensembl)
DR5GeneProductENSG00000196363 (Ensembl)
DVLGeneProductENSG00000107404 (Ensembl)
E2FGeneProductENSG00000101412 (Ensembl)
EIF4GeneProductENSG00000114867 (Ensembl)
ERK1/2GeneProductENSG00000102882 (Ensembl)
ERK2GeneProductENSG00000100030 (Ensembl)
ERK5GeneProductENSG00000166484 (Ensembl)
FAKGeneProductENSG00000169398 (Ensembl)
FIP200GeneProductENSG00000023287 (Ensembl)
FOXO1GeneProductENSG00000150907 (Ensembl)
FZDGeneProductENSG00000157240 (Ensembl)
GDPMetaboliteCHEBI:17552 (ChEBI)
GRB2GeneProductENSG00000177885 (Ensembl)
GSK3GeneProductENSG00000105723 (Ensembl)
GTPMetaboliteCHEBI:37565 (ChEBI)
HIF1AGeneProductENSG00000100644 (Ensembl)
HMGB1GeneProductENSG00000189403 (Ensembl)
IL-1BGeneProductENSG00000125538 (Ensembl)
JAKGeneProductENSG00000162434 (Ensembl)
JNK1-3GeneProductENSG00000107643 (Ensembl)
KIBRAGeneProductENSG00000113645 (Ensembl)
LATS1/2GeneProductENSG00000131023 (Ensembl)
LEFGeneProductENSG00000138795 (Ensembl)
LRPGeneProductENSG00000123384 (Ensembl)
MAPK14GeneProductENSG00000112062 (Ensembl)
MCL1GeneProductENSG00000143384 (Ensembl)
MDM2GeneProductENSG00000135679 (Ensembl)
MEK1/2GeneProductENSG00000169032 (Ensembl)
MEK3/6GeneProductENSG00000034152 (Ensembl)
MEK4/7GeneProductENSG00000065559 (Ensembl)
MEK5GeneProductENSG00000137764 (Ensembl)
MEKKGeneProductENSG00000095015 (Ensembl)
MKGeneProductENSG00000110492 (Ensembl)
MLKGeneProductENSG00000168404 (Ensembl)
MLST8GeneProductENSG00000167965 (Ensembl)
MMP2GeneProductENSG00000087245 (Ensembl)
MMP9GeneProductENSG00000100985 (Ensembl)
MNKGeneProductENSG00000079277 (Ensembl)
MSIN1GeneProductENSG00000119487 (Ensembl)
MSKGeneProductENSG00000100784 (Ensembl)
MST1/2GeneProductENSG00000173531 (Ensembl)
MTORGeneProductENSG00000198793 (Ensembl)
NF-KBGeneProductENSG00000109320 (Ensembl)
NF2/merlinGeneProductENSG00000186575 (Ensembl)
NLRP3GeneProductENSG00000162711 (Ensembl)
P14ARFGeneProductENSG00000147889 (Ensembl)
P16INK4AGeneProductENSG00000147889 (Ensembl)
P21GeneProductENSG00000124762 (Ensembl)
P53GeneProductENSG00000141510 (Ensembl)
PAK/RACGeneProductENSG00000149269 (Ensembl)
PDGFGeneProductENSG00000197461 (Ensembl)
PDK1GeneProductENSG00000152256 (Ensembl)
PI3KGeneProductENSG00000121879 (Ensembl)
PIGFGeneProductENSG00000151665 (Ensembl)
PIP2MetaboliteCHEBI:18348 (ChEBI)
PIP3MetaboliteCHEBI:16618 (ChEBI)
PRAS40GeneProductENSG00000204673 (Ensembl)
PRBGeneProductENSG00000251655 (Ensembl)
PTENGeneProductENSG00000171862 (Ensembl)
PUMAGeneProductENSG00000105327 (Ensembl)
Pro IL-1BGeneProductENSG00000125538 (Ensembl)
RAFGeneProductENSG00000132155 (Ensembl)
RAGEGeneProductENSG00000204305 (Ensembl)
RAPTORGeneProductENSG00000141564 (Ensembl)
RASGeneProductENSG00000174775 (Ensembl)
RHEBGeneProductENSG00000106615 (Ensembl)
RICTORGeneProductENSG00000164327 (Ensembl)
RNSMetaboliteQ225595 (Wikidata)
ROSMetaboliteCHEBI:70982 (ChEBI)
RSKGeneProductENSG00000160469 (Ensembl)
S6GeneProductENSG00000137154 (Ensembl)
S6KGeneProductENSG00000071242 (Ensembl)
SAV1GeneProductENSG00000151748 (Ensembl)
SFRPGeneProductENSG00000104332 (Ensembl)
SHCGeneProductENSG00000160691 (Ensembl)
SOSGeneProductENSG00000115904 (Ensembl)
SRCGeneProductENSG00000197122 (Ensembl)
STATGeneProductENSG00000115415 (Ensembl)
TAZGeneProductENSG00000102125 (Ensembl)
TCFGeneProductENSG00000081059 (Ensembl)
TEADGeneProductENSG00000187079 (Ensembl)
TEL2GeneProductENSG00000100726 (Ensembl)
TSC1GeneProductENSG00000165699 (Ensembl)
TSC2GeneProductENSG00000103197 (Ensembl)
TTI1GeneProductENSG00000101407 (Ensembl)
ULK1GeneProductENSG00000177169 (Ensembl)
VEGFGeneProductENSG00000112715 (Ensembl)
YAPGeneProductENSG00000137693 (Ensembl)
c-fosMetaboliteCHEBI:62519 (ChEBI)
c-junGeneProductENSG00000177606 (Ensembl)
fra-1 GeneProductENSG00000175592 (Ensembl)

Annotated Interactions

No annotated interactions

Retrieved from "https://classic.wikipathways.org/index.php/Pathway:WP5087"
Personal tools